A consistent approach to staging is required for the rational management of lung cancer. This paper was prepared at the request of the Standards Committee of the Canadian Thoracic Society, and reviews and discusses the relative merits of the available methods of staging. Whichever methods are chosen by a particular institution, the following points must be stressed. No patient can be considered automatically 'unresectable' when chest radiography and/ or computed tomography demonstrate adenopathy or only suggest local invasion. Clinical and/or radiographical evidence suggesting extensive local or metastatic disease should be evaluated as completely as possible before subjecting the patient to a possible 'nontherapeutic' thoracotomy. Finally, in some cases thoracotomy is required to decide whether the lesion is 'completely' resectable.
cancer (8) . Subsequently, it became apparent that, within the same clinical stage, there were subsets with significantly different prognoses. In 1986, Mountain (9) presented the currently used staging system, a combined effort by the AJCC and the International Union Against Cancer (Tables 1,2 ). An explanation of the classifications within this paper are outlined in Tables 1 and 2 . Within stage III there are further clinically distinct subgroups, each with different prognoses and treatment responses (Table 3 ) (10) . Therefore, the current TNM system will probably undergo further modification.
The staging process can be broken down into a clinical stage (cTNM) and a pathological stage (pTNM). cTNM, determined by clinical, radiographical and invasive studies, is used to plan the optimal therapeutic approach. pTNM, determined after surgery, suggests the prognosis and the role of adjuvant regimens (Table 4) (11, 12) . Analysis of the resected specimen by using cell biological techniques may be added to the assesment of pTNM and affect postoperative treatment planning (10) .
The TNM system is applicable to both NSCLC and small cell lung cancer (SCLC). SCLC, however, is usually described as 'limited' or 'extensive' based on whether it can be encompassed by one radiation port (13) .
As important as these methodologies are, it is equally important to determine whether the patient has sufficient cardiopulmonary reserves to undergo a resection.
METHODS OF STAGING
A number of staging methods can assess each of the tumour (T), node (N) and metastases (M) descriptors (Table  5 ). These will be discussed in turn.
Assessing T status
Clinical examination: Examination may suggest advanced local disease (Table 6 ). Pulmonary symptoms are not specific enough to rule out curative resection by themselves (14, 15) . However, extrapulmonary intrathoracic symptoms imply advanced local disease that may well preclude curative resection and require further investigation before proceeding to thoracotomy. Chest radiograph: While not exact in determining the true extent of endobronchial disease, the chest radiograph (CXR) can provide evidence of intrathoracic spread or invasion, such as diaphragmatic elevation (implying possible phrenic nerve involvement), vertebral or rib lesions, pleural or pericardial effusion, and synchronous (more than one primary growth) or metastatic lesions. Computed tomography: Computed tomography (CT) pro- (16) . More specifically, it is important to evaluate the following features: less than 3 cm of contact in one cut between the tumour and mediastinal structure in question; less than 90 degrees of contact with the aorta (ie, one-quarter of the circumference); and/or the presence of an intact mediastinal fat plane. If any one of these is present, resection is possible in up to 97% of cases (16) . In terms of chest wall involvement, CT has an accuracy of 39%, specificity of 40% and sensitivity of 39% when considering features such as pleural thickening, obtuse angle between mass and adjacent pleural surface, and/or thickening of pleural fat (17) . Prethoracotomy thoracoscopy appears to be a useful adjunct in such settings (2) .
Magnetic resonance imaging:
While not recommended as a routine study, magnetic resonance imaging (MRI) is more accurate than CT in determining the degree of vertebral, spinal canal or (arguably) chest wall invasion, and may be the modality of choice for evaluating superior sulcus tumours (14) . MRI defines relationships to vessels but tends to overestimate mediastinal invasion (18) . Bronchoscopy: Bronchoscopy is important in determining the endobronchial T stage and should be done by the surgeon just before thoracotomy at the same anesthetic sitting, even if already performed by a pulmonologist, because it may have direct impact on the proposed plan for resection (1) . Some patients with T3 or even T4 lesions may be candidates for a sleeve resection, and bronchoscopic biopsies are needed to ensure that there is no subepithelial spread beyond the limits of resection (19) (20) (21) assessment of pleural, chest wall and mediastinal invasion (2, 22) . It is particularly important in the presence of pleural effusion because the resectability rate, even in the presence of cytologically negative fluid, is as low as 5.5% (23) . Some groups advocate its routine use before all surgery (22) .
Assessing N status
Clinical examination: Examination of the neck may identify adenopathy (N3) that would require biopsy confirmation. This is particularly important in the presence of superior sulcus tumours. Patients with left-sided lesions and hoarseness may have fixed N2 nodes involving the recurrent laryngeal nerve. If confirmed histologically, this is a contraindication to resection, as is extrapulmonary intrathoracic symptoms due to adenopathy. CXR: Except when gross adenopathy is identified, CXR does not adequately assess lymph node spread. Gross mediastinal adenopathy noted on plain CXR is associated with an extremely poor prognosis, with three-year survival averaging 9% (24) . Biopsy confirmation of metastatic involvement is required. CT: CT is currently the most effective noninvasive method of assessing possible mediastinal lymph node metastases (14) . CT evidence of adenopathy is usually nodes with a short axis diameter (1.0 cm). A meta-analysis of CT accuracy in defining mediastinal node involvement ascribed a sensitivity of 79%, a specificity of 78% and an overall accuracy of 80% (25) . Between 5% and 30% of 'abnormal' nodes are positive for cancer, while as many as 15% of patients with 'normal' nodes are positive (2, 4, 26) . The false negative rate increases in the presence of adenocarcinoma, large cell tumours and with all central T3 cancers (27, 28) . Thus, surgical resectability cannot be excluded solely on the basis of CT evidence of adenopathy, and, by the same token, certain lesions are associated with increased risk of mediastinal nodal involvement despite a 'negative' CT. Positron emission tomography: Positron emission tomography, in conjunction with F-18-fluorodeoxyglucose, has shown some promise in detecting superior mediastinal and supraclavicular involvement, although inflammatory lesions may cause false positive readings (29) (30) (31) (32) . These findings need to be confirmed histologically. Mediastinoscopy and mediastinotomy: Mediastinoscopy is safe (percentage morbidity) and, when used routinely, reduces nontherapeutic thoracotomy rates to 5% (5, 33) . It identifies patients with false positive CT mediastinal adenopathy, as well as the subset that are found to have 'minimal' (intracapsular spread without fixation, solitary, lowest station) mediastinal nodal involvement (with 25% to 40% fiveyear survival following complete resection) (1, 2, 4, 20) . Finally, a proportion of these patients may be eligible for enrolment into neoadjuvant protocols, and many of these protocols require invasive staging (1, 2, 4, 10, 11, 20, 34, 35) . However, it is not clear whether, in the absence of CT evidence of mediastinal adenopathy, mediastinoscopy increases survival advantage (1, 26, 36, 37) . Thus, depending on what a particular centre considers to be the upper limit of normal, many centres advocate 'selective' mediastinoscopy ( 
nodes. Biopsy of the aortopulmonary and para-aortic and/or subaortic (anterior mediastinal) nodes (stations 5 and 6) is indicated if there is evidence of enlarged aortopulmonary window nodes and cervical mediastinoscopy is negative. The primary concern is whether the nodes are fixed to the pulmonary artery because the five-year survival rate after complete resection in the presence of resectable subaortic disease only approaches that of survival after resection of N1 disease (38, 39) . While traditionally performed by anterior mediastinotomy, extended cervical mediastinoscopy, which provides a single staging method for left upper lobe tumours, is performed, but only at a few centres (40) . Bronchoscopy: At the start of the procedure, suspected vocal cord paralysis can be evaluated. This may confirm CT evidence of extensive N2 nodal disease with involvement of the recurrent nerve. Carinal widening or other evidence of adenopathy can be detected, and these nodal areas biopsied, with a Wang needle with a sensitivity of 50% and specificity of 96% (41, 42) . Some centres obtain a CT before initial bronchoscopy so that accessible areas of adenopathy can be biopsied at that time and, thus, avoid mediastinoscopy in many instances. However, the use of this approach varies between institutions depending on the confidence and skill of both the bronchoscopist and pathologist. One of the authors of this report has used this technique to biopsy multiple nodal areas including both right tracheobronchial nodes. Preliminary results suggest that the yield is similar to mediastinoscopy. When lymph tissue is obtained from suspicious nodes and is negative for cancer, our current practice is to perform mediastinoscopy. If the area is 'missed', an alternative that is being evaluated is bronchoscopic Wang needle biopsy with real-time CT guidance. Fine needle aspiration: Clinically palpable neck nodes can be aspirated or biopsied under local anesthesia (14) . Areas of adenopathy, both within and beyond the 'range' of mediastinoscopy, have been successfully biopsied using CT-guided techniques with a reported sensitivity of 88% and specificity of 100% (43) . The results are operator-dependant, and each institution must evaluate its own results before making firm conclusions regarding the use of this method in their own setting. Transesophageal ultrasound-guided needle biopsy has also been described for selected patients (44) . Scalene node biopsy: While palpable scalene nodes should be biopsied, routine biopsies have not been performed for the past 20 to 30 years. However, a recent report documented microscopic involvement of the scalene nodes in 15% of patients with positive N2 disease and 68% of patients with contralateral disease, and recommended routine mediastinoscopic scalene node biopsies in such patients (45) . Thoracoscopy: Thoracoscopy can be used to biopsy many of the nodal areas, but it is particularly useful for assessing the posterior subcarinal and aortopulmonary window nodes, and has been advocated as a routine prethoracotomy staging tool by some centres (2, 22) . Mediastinoscopy still appears superior in its ability to assess the upper mediastinal nodes (2,14).
Assessing M status
Clinical examination: While the presence of extrathoracic, nonmetastatic symptoms (Table 6) does not preclude curative resection, generalized debility and/or weight loss is often an indication of widespread disease (14) . Approximately 1% of patients have evidence of cutaneous metastases that should be biopsied. Focal neurological, bony or abdominal symptoms should prompt head CT, bone scan or abdominal CT, respectively. Elevated serum alkaline phosphatase (liver or bone fraction) or calcium should prompt a similar evaluation with imaging studies. Radiographic studies: CXR and/or CT may demonstrate rib changes or other bony lesions consistent with metastases. Synchronous or intrapulmonary metastatic lesions may also be detected.
It is routine to include the upper abdomen in the CT evaluation of pulmonary malignancies. Approximately 7% of patients have evidence of adrenal or hepatic involvement (46) . The risk of adrenal enlargement due to a metastasis increases if the adrenal is greater than 3 cm in diameter. Suspicious lesions must be confirmed by biopsy before denying an otherwise resectable patient an opportunity for curative surgery.
Many centres feel that it is not warranted to obtain routine bone scans or head CTs in patients with NSCLC that appear to be resectable without laboratory or clinical evidence of metastases (47, 48) . Others feel that all nonsquamous NSCLC, as well as all stage III tumours, should have routine cerebral imaging because of the greater propensity for microscopic early spread (49) .
A positive bone scan should be followed by appropriate correlative plain radiographs for confirmation. A negative radiograph in the presence of a positive bone scan does not exclude metastatic disease, and further investigation, including MRI, CT or biopsy, may be required.
THE ROLE OF THORACOTOMY IN STAGING
It is apparent from the above discussion that a proportion of patients may require thoracotomy to determine ultimately whether complete resection is possible. In addition, complete staging at thoracotomy determines both prognosis and the role of adjuvant treatments (10, 50) . A more difficult and controversial area is how to determine at thoracotomy that resection will not benefit a patient, especially because there is an emotional pressure 'to do something'. Careful exploration may reveal invasion of mediastinal structures or the vertebrae that would, except in rare circumstances, preclude curative resection. Some centres perform mediastinal lymph node dissection before any resection because they feel that extensive spread precludes curative surgery.
INTEGRATING STAGING INTO ATREATMENT PLAN FOR NSCLC
Apparently operable NSCLC: It appears that T1 and T2 lesions with no evidence of mediastinal adenopathy on CT scan do not require more invasive staging. This does not appear to increase the incidence of 'nontherapeutic' thoracoto-mies or decrease the cure rate (34) . Staging of T3 lesions without evidence of adenopathy is controversial. Survival is markedly reduced in T3N2 stage IIIA tumours, and if a particular centre plans induction regimens for these patients, biopsy of the upper mediastinal N2 nodes should be performed routinely (2) . Other centres prefer to go straight to thoracotomy, with plans for complete mediastinal node dissection and adjuvant therapy, although there is no proven survival benefit (11, 20, 50) . Apparently inoperable NSCLC: Curative resection should not be withheld on the basis of indeterminate radiographical findings alone. Central lesions that appear to invade the mediastinum but are otherwise operable may require thoracotomy for definition (16) . Occasional survivors are reported from minimal resection of the vena cava, aorta, esophagus, atrium and vertebral body (11, 20) . Prethoracotomy mediastinoscopy should be performed where this possibility is suggested by CT scan because central T3N2 and T4N2 lesions treated by resection alone are associated with essentially no chance of five-year survival.
Patients with adenopathy on CT should also undergo more invasive staging by one of the methods described previously. Ten per cent of patients with NSCLC and positive N2 disease have single, ipsilateral, intracapsular spread only and are still candidates for resection (1, 2, 4, 20) . The remainder may be candidates for neoadjuvant therapy. Such regimens for stages IIIA and IIIB have been described, with a subsequent complete resection rate as high as 73% (11, 20, 35) .
Although there have been occasional reports of survivors with NSCLC with stage IV disease following surgery, the role of resection has generally been limited to patients with isolated, resectable, cranial metastases (11, 20) . Usually craniotomy precedes thoracotomy to ensure complete resectability, the absence of other occult metastases and full patient recovery. Resection in patients with isolated adrenal metastases has also been described with a 38% three-year survival rate, but this approach is still investigational (51) . High risk patients: It is important to consider both 'resectability' (ie, the tumour) and 'operability' (ie, the patient's ability to tolerate surgery). A more aggressive approach to staging is justifiable in patients whose general medical condition (usually cardiopulmonary) puts them at high risk for thoracotomy. Individuals with primary cardiac limitations may require stress tests, echocardiography and possibly coronary angiography. Patients with correctable coronary disease may undergo preoperative angioplasty or bypass, or, rarely, simultaneous coronary bypass and lung resection (52) . The major question is whether pulmonary reserves are adequate to tolerate the proposed resection (53, 54) . Unfortunately, no single preoperative test is sufficiently accurate in predicting the risk of surgery, but rather an integrated approach, taking into account clinical judgement and a number of physiological variables, is often needed (Figure 1) 1 or DLCO will be less than 40%, a maximum progressive incremental exercise is indicated. If maximum exercise capacity is less than 30% predicted or maximum oxygen consumption is less than 10 mL/kg/min, the risk of resection is extremely high but does not absolutely preclude surgery (57) .
Intraoperative studies may have a role in determining how well a resection can be tolerated. Initial data suggest that long term cardiac disability (but not mortality) may be predicted at the time of 'test clamping' of the pulmonary artery by recording a right ventricular ejection fraction (RVEF) of 35%, a pulmonary vascular resistance (PVR) of at least 200 dyne·s·cm -5 and/or a PVR:RVEF ratio of 5.0 (57). Some groups use a variety of 'angioplastic' and 'bronchoplastic' reconstructions to preserve as much functional lung as possible in patients who are identified as high risk (19, 21, 58) . Patients with peripheral T1 lesions without evidence of mediastinal metastases who are not suitable for thoracotomy may be considered for thoracoscopic wedge resection, although the risk of local recurrence is increased (59) . Patients whose pulmonary reserves fail to achieve institutional 'limits' should not be arbitrarily rejected for surgery, but rather all possible options should be discussed (54) . Many patients improve with preoperative pulmonary therapy, bronchodilators and smoking cessation, and on retesting may become candidates for surgery. Improvements in postoperative care, especially pain management, have resulted in decreased morbidity in high risk patients following thoracotomy (54, 55) . Each centre needs to evaluate its own outcomes to determine individual limits. Local recurrence and restaging following induction therapy: The approach to staging in the setting of local recurrence or following induction therapy is the same as with the initial workup, except that mediastinoscopy (redoing or following chemotherapy) is more hazardous, and most centres advocate cerebral CT and bone scans as mandated by symptoms and signs, if not 'routinely'. Ideally, suspicious mediastinal adenopathy should be biopsied before thoracotomy by one of the techniques described earlier because completion pneumonectomy is associated with increased operative risk (60) .
STAGING SCLC
The role of surgery in SCLC is limited because chemotherapy is considered the primary treatment. Staging is mainly used for prognosis and to determine eligibility for treatment protocols (61) . However, application of TNM staging reveals that stage I SCLC can be resected with 25% fiveyear survival or higher, assuming chemotherapy is also given. Frequently, stage I SCLC is diagnosed after resecting a solitary pulmonary nodule when this diagnosis was not anticipated preoperatively. Extensive staging is still required. Bone marrow biopsy (unilateral) is usually included, although its worth has been questioned (61) . Chemotherapy is mandatory, either preoperatively or postoperatively, because patients with apparent stage I SCLC should still be regarded as having systemic disease. Patients with lesions that are found to be stage II at thoracotomy should receive postoperative adjuvant therapy. Some preliminary data suggest that patients with preoperative evidence of N1 or minimal N2 disease benefit from induction chemotherapy and adjuvant surgery (62, 63) . It should be stressed that chemotherapy remains the primary treatment for SCLC, and surgery may be used as an alternative to radiotherapy for local control, in some cases under strict investigational protocols only. No randomized studies have compared adjuvant surgery with adjuvant chemotherapy and radiation. Approach to diagnosis of adenocarcinoma: Diagnosis of adenocarcinoma, unlike other cell types that commonly arise in the lung, does not necessarily imply primary lung cancer, and on pathological examination alone it may be difficult to impossible to confirm a lung origin. One therefore needs to consider the possibility of metastatic disease, even when the lesion appears to be solitary. This applies to bronchioloalveolar carcinoma (BAC) as well, in that approximately 16% of adenocarcinomas metastatic to lung may simulate BAC in their growth pattern (64) . It is also important to recognize that BAC has a unique propensity for multifocal growth with a reported incidence of 25% (65) . Further, a prospective combined CXR/CT scan study showed that multicentricity in BAC was missed in 37% of cases (66) .
STAGING CARCINOID TUMOURS
Carcinoid tumours have been considered a tumour type in a spectrum of Kulchitsky cell or neuroendocrine neoplasms, which range from typical carcinoid through atypical carcinoid and, finally, SCLC (67) . Typical carcinoids have low malignant potential, with less than 5% incidence of lymph node metastases and greater than 80% cure rates with surgery (68). Atypical carcinoids have an incidence of lymphatic metastases in up to 70%, with a 10-year survival of less than 50% (68, 69) . Clinical evidence of carcinoid syndrome implies atypical features, a large lesion or metastases, with rare exceptions (70) . The most recent authoritative classification of neuroendocrine neoplasms adds a tumour type called large cell neuroendocrine carcinoma (71) . This is a high grade carcinoma that fits in the spectrum somewhere between atypical carcinoid and SCLC, with a prognosis approaching that of SCLC.
Surgery is still the primary mode of treatment, but accurate intraoperative staging may confirm lymphatic metastases, which may indicate a role for adjuvant therapy (69) .
STAGING METASTASES TO THE LUNG
Resection can be considered for pulmonary metastases from extrathoracic malignancies under certain circumstances (Table 8) . Some lesions (breast, thyroid, renal cell, melanoma and colon) may be associated with endobronchial metastases, necessitating bronchoscopy. If the primary lesion is associated with lymphatic metastases and there is evidence of mediastinal adenopathy, these potential N2 nodes should be biopsied (72) .
SUMMARY
Staging lung cancer requires a physiological as well as pathological assessment. It is laborious, and many patients are unsuitable for resection. There are some 'grey' areas where definite recommendations cannot be made, and each centre needs to review its own results. Lymphadenopathy can be assessed by mediastinoscopy, bronchoscopy, CT-guided needle biopsy and/or thoracoscopy. There is evidence for 'selective' mediastinoscopy, but there is also strong support for 'routine' mediastinoscopy. Thoracoscopy can be viewed in the same fashion. The definition of what constitutes a 'physiological' high risk patient also varies between centres. Despite all of these issues, there are three basic 'guidelines'.
1. No patient can be considered automatically 'unresectable' when chest radiography and/or CT demonstrates adenopathy or only suggests local invasion. 2. Clinical and/or radiographical evidence suggesting extensive local or metastatic disease should be evaluated as completely as possible before subjecting the patient to a possible 'nontheraputic' thoracotomy. 3. In some cases, thoracotomy is required to determine 
